The FDA has notified Reviva Pharmaceuticals Holdings Inc RVPH that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia.
- The FDA has also signed off an additional Phase 3 trial focused on the long-term safety of brilaroxazine in patients with schizophrenia.
- Related: Reviva Pharma Stock Trading Higher On Detailed Positive Schizophrenia Study Results.
- Both Phase 3 trials will be initiated simultaneously by the end of January 2022.
- Price Action: RVPH shares are up 16.2% at $3.45 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareFDAMoversTrading IdeasGeneralBriefsPhase 3 TrialSchizophreniawhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in